Hillsdale Investment Management Inc. Has $166,000 Stock Holdings in Surmodics, Inc. (NASDAQ:SRDX)

Hillsdale Investment Management Inc. lifted its position in shares of Surmodics, Inc. (NASDAQ:SRDX) by 15.7% during the 4th quarter, Holdings Channel reports. The firm owned 4,570 shares of the company’s stock after purchasing an additional 620 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Surmodics were worth $166,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Surmodics by 2.4% during the 3rd quarter. Vanguard Group Inc. now owns 846,164 shares of the company’s stock worth $27,153,000 after purchasing an additional 19,635 shares during the last quarter. Acadian Asset Management LLC grew its stake in Surmodics by 18.8% in the 3rd quarter. Acadian Asset Management LLC now owns 354,738 shares of the company’s stock valued at $11,377,000 after buying an additional 56,012 shares during the last quarter. Salem Investment Counselors Inc. grew its stake in Surmodics by 1.3% in the 4th quarter. Salem Investment Counselors Inc. now owns 129,940 shares of the company’s stock valued at $4,723,000 after buying an additional 1,700 shares during the last quarter. Russell Investments Group Ltd. grew its stake in Surmodics by 6.4% in the 4th quarter. Russell Investments Group Ltd. now owns 67,845 shares of the company’s stock valued at $2,466,000 after buying an additional 4,066 shares during the last quarter. Finally, Panagora Asset Management Inc. grew its stake in Surmodics by 109.8% in the 4th quarter. Panagora Asset Management Inc. now owns 44,664 shares of the company’s stock valued at $1,624,000 after buying an additional 23,379 shares during the last quarter. 96.63% of the stock is currently owned by institutional investors and hedge funds.

Surmodics Stock Performance

Shares of NASDAQ:SRDX opened at $34.89 on Wednesday. The company’s 50 day moving average price is $29.11 and its two-hundred day moving average price is $32.01. Surmodics, Inc. has a 12-month low of $16.79 and a 12-month high of $39.41. The firm has a market cap of $497.53 million, a PE ratio of 36.73 and a beta of 1.04. The company has a quick ratio of 3.59, a current ratio of 4.39 and a debt-to-equity ratio of 0.24.

Surmodics (NASDAQ:SRDX) last announced its earnings results on Wednesday, May 1st. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.43. Surmodics had a net margin of 9.44% and a return on equity of 13.30%. The firm had revenue of $31.96 million for the quarter, compared to analyst estimates of $28.79 million. During the same quarter in the prior year, the business posted ($0.40) EPS. Equities research analysts predict that Surmodics, Inc. will post -0.52 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on SRDX. StockNews.com lowered shares of Surmodics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, April 24th. Needham & Company LLC decreased their price target on shares of Surmodics from $47.00 to $43.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Finally, Barrington Research restated an “outperform” rating and set a $71.00 target price on shares of Surmodics in a research report on Thursday, May 2nd.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).